VEGFA and neoplasm: Tyrosine kinase inhibitors (TKIs) incorporate a broad range of small molecule therapeutics which may target oncogenes (e.g. Epidermal Growth Factor Receptor, EGFR) or other targets in the tumour microenvironment (e.g. Vascular Endothelial Growth Factor, VEGF).